OncoMatch/Clinical Trials/NCT03911388
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Is NCT03911388 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies G207 for neoplasms, brain.
Treatment: G207 — This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Tumor Agnostic
Demographics
Prior therapy
Must have received: surgery
progressive or recurrent despite standard care including surgery, radiotherapy, and/or chemotherapy
Must have received: radiation therapy
progressive or recurrent despite standard care including surgery, radiotherapy, and/or chemotherapy
Must have received: chemotherapy
progressive or recurrent despite standard care including surgery, radiotherapy, and/or chemotherapy
Lab requirements
Blood counts
absolute neutrophil count > 1000/mm3, platelets > 100,000/mm3, prothrombin time (pt) or partial thromboplastin time (ptt) < 1.3 x control
Kidney function
creatinine within normal institutional limits or creatinine clearance >60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal
Liver function
total bilirubin < 1.5 mg/dl, transaminases < 3 times above the upper limits of the institutional norm
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's of Alabama · Birmingham, Alabama
- St. Louis Children's Hospital · St Louis, Missouri
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03911388 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received surgery and radiation therapy.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 3 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages